Get access

BRCA1 germline mutations in Chinese patients with hereditary breast and ovarian cancer

Authors

  • N. LI,

    1. *Department of Gynecological Oncology, Cancer Hospital and †National Laboratory of Molecular Oncology, Cancer Institute, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China; and ‡Peking University School of Oncology, Beijing Institute for Cancer Research, Beijing Cancer Hospital, Beijing, China
    Search for more papers by this author
  • X. ZHANG,

    1. *Department of Gynecological Oncology, Cancer Hospital and †National Laboratory of Molecular Oncology, Cancer Institute, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China; and ‡Peking University School of Oncology, Beijing Institute for Cancer Research, Beijing Cancer Hospital, Beijing, China
    Search for more papers by this author
  • Y. CAI,

    1. *Department of Gynecological Oncology, Cancer Hospital and †National Laboratory of Molecular Oncology, Cancer Institute, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China; and ‡Peking University School of Oncology, Beijing Institute for Cancer Research, Beijing Cancer Hospital, Beijing, China
    Search for more papers by this author
  • X. XU,

    1. *Department of Gynecological Oncology, Cancer Hospital and †National Laboratory of Molecular Oncology, Cancer Institute, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China; and ‡Peking University School of Oncology, Beijing Institute for Cancer Research, Beijing Cancer Hospital, Beijing, China
    Search for more papers by this author
  • L. ZHANG,

    1. *Department of Gynecological Oncology, Cancer Hospital and †National Laboratory of Molecular Oncology, Cancer Institute, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China; and ‡Peking University School of Oncology, Beijing Institute for Cancer Research, Beijing Cancer Hospital, Beijing, China
    Search for more papers by this author
  • K.-F. PAN,

    1. *Department of Gynecological Oncology, Cancer Hospital and †National Laboratory of Molecular Oncology, Cancer Institute, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China; and ‡Peking University School of Oncology, Beijing Institute for Cancer Research, Beijing Cancer Hospital, Beijing, China
    Search for more papers by this author
  • L.-Y. WU,

    Corresponding author
    1. *Department of Gynecological Oncology, Cancer Hospital and †National Laboratory of Molecular Oncology, Cancer Institute, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China; and ‡Peking University School of Oncology, Beijing Institute for Cancer Research, Beijing Cancer Hospital, Beijing, China
      Address correspondence and reprint requests to: Ling-Ying Wu, MD, Department of Gynecological Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China. Email: wulingying@csco.org.cn
    Search for more papers by this author
  • M.-R. WANG

    Corresponding author
    1. *Department of Gynecological Oncology, Cancer Hospital and †National Laboratory of Molecular Oncology, Cancer Institute, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China; and ‡Peking University School of Oncology, Beijing Institute for Cancer Research, Beijing Cancer Hospital, Beijing, China
      Ming-Rong Wang, PhD, National Laboratory of Molecular Oncology, Cancer Institute, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China. Email: wangmr04@126.com
    Search for more papers by this author

Address correspondence and reprint requests to: Ling-Ying Wu, MD, Department of Gynecological Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China. Email: wulingying@csco.org.cn and Ming-Rong Wang, PhD, National Laboratory of Molecular Oncology, Cancer Institute, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China. Email: wangmr04@126.com

Abstract

Abstract.  Li N, Zhang X, Cai Y, Xu X, Zhang L, Pan K-F, Wu L-Y, Wang M-R. BRCA1 germline mutations in Chinese patients with hereditary breast and ovarian cancer. Int J Gynecol Cancer 2006;16(Suppl. 1):172–178.

The role of germline BRCA1 mutations in hereditary breast and ovarian cancer (HBOC) has been well established in women in Western countries. However, relatively few studies have been carried out in Chinese population. In the present study, we investigated the frequency and spectrum of germline BRCA1 mutations in Chinese HBOC patients, all of whom were from northern part of China. A total of 25 women with HBOC and ten relatives were analyzed. Mutation screening was performed by a combination of denaturing high-performance liquid chromatography and sequencing. Seven protein-truncating mutations were identified. They were 667delG, 3347A → T, 3478del5, 4255delCT, 1235A → G, 2064G → T, and 5589del8. The first four of the mutations were putative ones never reported before. The prevalence of the protein-truncating mutations in this HBOC series was 40.0%, which is similar to that observed in Western hereditary ovarian cancer patients but higher than that reported in Chinese women with sporadic breast and ovarian cancer. Among the ten relatives we analyzed, six shared the same mutations with their affected relatives. No ovarian cancer was detected after 19 months of follow-up. This study showed that BRCA1 mutations play an important role in Northern Chinese HBOC.

Get access to the full text of this article

Ancillary